NVO Stock Price Today (July 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-07-17
Novo Nordisk A/S (NVO) is trading at $50.32, down 2.25% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.41 (-5.8% upside).
- Volatility remains elevated (23.53% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (24.00% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $337.73B
P/E Ratio
Forward P/E: 14.79
Revenue Growth
Year over Year
Analyst Target
+-5.8% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 61.84)
- Fundamentals say: Caution warranted (high leverage concerns)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $146.38B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $71.80—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.53% annualized volatility and β=1.02, the stock exhibits moderate correlation to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking's latest program seeks to push the envelope in weight loss efficacy.
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win
Novo Nordisk is finally getting one up on its biggest rival.
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may not be the company that makes the drug.
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.
3 High-Yield Dividend Stocks to Buy and Hold
All three can be bought on the dip.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.
Novo Nordisk (NYSE:NVO) Wins First EU Approval For Oral Wegovy In Weight Management
Novo Nordisk (NYSE:NVO) received European Commission marketing authorization for its oral Wegovy pill for weight management. The approval covers the European Union and represents the first GLP-1 receptor agonist in pill form cleared for this use in the region. This decision follows growing use of obesity therapies in the U.S. and other key markets. Novo Nordisk is already a major player in diabetes and obesity care, and the oral Wegovy pill gives the company another way to reach patients...
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $50.32. The RSI (14-day) is at 61.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $47.41 implies 5.8% downside from current levels. Volatility is moderate at 23.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 12.07, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 14.79. The PEG ratio is 3.54, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.21. Price-to-Sales is 0.51. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.41. This represents a 5.8% downside from the current price of $50.32. The range spans from a low target of $39.51 to a high target of $62.92, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 3.58%. The annualized dividend rate is $11.70 per share. The payout ratio is 42.6%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-03-30T00:00:00.000Z.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Elevated short interest (77.0% of float) suggests significant bearish sentiment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $146.38B. The debt-to-equity ratio is 72.09, which is moderate and generally manageable for most companies. The current ratio is 0.79, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.54. The company holds $21.63B in cash and equivalents. Free cash flow is negative at $-12,039,249,920, which could limit the company's ability to manage debt obligations.